FCM
AXSM icon

Frontier Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Frontier Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.2M Buy
254,280
+51,214
+25% +$11.1M 0.58% 44
2026
Q1 		$34.3M Buy
203,066
+45,375
+29% +$7.84M 0.35% 99
2025
Q4 		$28.8M Buy
157,691
+31,309
+25% +$4.37M 0.31% 123
2025
Q3 		$15.3M Buy
126,382
+97,540
+338% +$11M 0.14% 211
2025
Q2 		$3.01M Sell
28,842
-14,419
-33% -$1.53M 0.03% 281
2025
Q1 		$5.05M Sell
43,261
-9,507
-18% -$1.08M 0.06% 254
2024
Q4 		$4.46M Sell
52,768
-67,772
-56% -$6.23M 0.04% 258
2024
Q3 		$10.8M Buy
120,540
+24,513
+26% +$2.14M 0.1% 209
2024
Q2 		$7.73M Sell
96,027
-9,317
-9% -$690K 0.08% 228
2024
Q1 		$8.41M Buy
105,344
+10,456
+11% +$878K 0.08% 225
2023
Q4 		$7.55M Sell
94,888
-65,788
-41% -$4.4M 0.08% 214
2023
Q3 		$11.2M Sell
160,676
-61,544
-28% -$4.6M 0.12% 183
2023
Q2 		$16M Buy
222,220
+181,515
+446% +$13.4M 0.15% 168
2023
Q1 		$2.51M Sell
40,705
-48,706
-54% -$3.2M 0.03% 247
2022
Q4 		$6.9M Buy
+89,411
New +$5.34M 0.08% 215

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Frontier Capital Management's AXSM Position: Q2 2026 in Review

Frontier Capital Management increased its Axsome Therapeutics (AXSM) stake by 25% in Q2 2026, buying an estimated $11.1M and bringing the position to 254,280 shares worth $62.2M. The position accounts for 0.58% of the portfolio, ranked #44.

Frontier Capital Management first reported a position in AXSM in Q4 2022 and has held it in 15 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Frontier Capital Management held 254,280 shares of Axsome Therapeutics worth $62.2M as of Q2 2026.
  • Frontier Capital Management bought 51,214 Axsome Therapeutics shares in Q2 2026, an estimated $11.1M.
  • Axsome Therapeutics made up 0.58% of Frontier Capital Management's portfolio in Q2 2026, its #44 holding.
  • Frontier Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.